Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126924771 | 12692477 | 1 | I | 20160824 | 20160829 | 20160829 | EXP | GB-MHRA-EYC 00144005 | GB-GLENMARK GENERICS (EUROPE) LTD.-2016GMK024071 | GLENMARK | 0.00 | Y | 0.00000 | 20160829 | MD | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126924771 | 12692477 | 1 | PS | EZETIMIBE. | EZETIMIBE | 1 | Oral | 10 MG, UNK | N | 78560 | 10 | MG | |||||||
126924771 | 12692477 | 2 | I | ROSUVASTATIN CALCIUM. | ROSUVASTATIN CALCIUM | 1 | Oral | 20 MG, UNK | N | 0 | 20 | MG | |||||||
126924771 | 12692477 | 3 | C | CALCEOS | CALCIUM CARBONATECHOLECALCIFEROL | 1 | Unknown | UNK | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126924771 | 12692477 | 1 | Product used for unknown indication |
126924771 | 12692477 | 2 | Product used for unknown indication |
126924771 | 12692477 | 3 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126924771 | 12692477 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126924771 | 12692477 | Acute kidney injury | |
126924771 | 12692477 | Drug interaction | |
126924771 | 12692477 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |